首页> 外文期刊>European Journal of Cancer Supplements >55 Low frequency of breast cancer recurrence following introduction of adjuvant trastuzumab in HER-2 positive early breast cancer: an audit of relapses in a UK Cancer Centre and the implications for future practice

【24h】

55 Low frequency of breast cancer recurrence following introduction of adjuvant trastuzumab in HER-2 positive early breast cancer: an audit of relapses in a UK Cancer Centre and the implications for future practice

机译：55在HER-2阳性早期乳腺癌中引入辅助曲妥珠单抗后乳腺癌复发频率低：对英国癌症中心复发的审计及其对未来实践的影响

获取原文

掌桥外文数据库（机构版） >>

开具论文收录证明 >>

文献代查 >>

页面导航

著录项
相似文献
相关主题

著录项

来源
《European Journal of Cancer Supplements》 |2010年第3期|共2页
作者
S.Haney; P.Stephens; P.Gamble; M.Verrill;
展开▼
作者单位

展开▼
收录信息
原文格式 PDF
正文语种
中图分类肿瘤学;
关键词

相似文献

外文文献
中文文献
专利

1. 55 Low frequency of breast cancer recurrence following introduction of adjuvant trastuzumab in HER-2 positive early breast cancer: an audit of relapses in a UK Cancer Centre and the implications for future practice [J] . S.Haney, P.Stephens, P.Gamble, European Journal of Cancer Supplements . 2010,第3期

机译：55在HER-2阳性早期乳腺癌中引入辅助曲妥珠单抗后乳腺癌复发频率低：对英国癌症中心复发的审计及其对未来实践的影响
2. Human epidermal growth factor receptor 2-positive breast cancer relapsing post-adjuvant trastuzumab: pattern of recurrence, treatment and outcome. [J] . Krell J, James CR, Shah D, Clinical breast cancer . 2011,第3期

机译：人表皮生长因子受体2阳性乳腺癌复发辅助曲妥珠单抗：复发，治疗和结局的模式。
3. Trastuzumab retreatment after relapse on adjuvant trastuzumab therapy for human epidermal growth factor receptor 2-positive breast cancer: Final results of the retreatment after herceptin adjuvant trial [J] . LángI., BellR., FengF.Y., Clinical oncology . 2014,第2期

机译：曲妥珠单抗在人表皮生长因子受体2阳性乳腺癌的辅助治疗中复发后的曲妥珠单抗再治疗：赫赛汀辅助试验后再治疗的最终结果
4. Elevated WBP2 Expression in HER2-Positive Breast Cancers Correlates with Sensitivity to Trastuzumab-Based Neo-Adjuvant Therapy: A Retrospective and Multicentric Study [C] . Yoon Pin Lim International Molecular Medicine Tri-Conference. . 2019

机译：HER2阳性乳腺癌中的WBP2表达升高与基于曲妥珠单抗的新辅助治疗的敏感性相关：回顾性和多中心研究
5. Impact of HER-2/neu detection by fluorescence in situ hybridization (FISH) on trastuzumab therapy in the treatment of metastatic breast cancer. [D] . Subongkot, Suphat. 2003

机译：荧光原位杂交（FISH）检测HER-2 / neu对曲妥珠单抗治疗转移性乳腺癌的影响。
6. Exploring the use and impact of adjuvant Trastuzumab for HER2-positive breast cancer patients in a large UK cancer networkDo the results of international clinical trials translate into a similar benefit for patients in South East Wales? [O] . R M Webster, J Abraham, N Palaniappan, 2012

机译：探索大型英国癌症网络中辅助曲妥珠单抗对HER2阳性乳腺癌患者的使用和影响国际临床试验的结果是否可以为东南威尔士的患者带来类似的好处？
7. Estimating recurrences prevented from using trastuzumab in HER-2/neu-positive adjuvant breast cancer in the United States [O] . Mark D. Danese, Deepa Lalla, Melissa Brammer, 2010

机译：估计在美国在Her-2 / Neu-阳性辅助乳腺癌中使用曲妥珠单抗使用rstuzumab

获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

客服微信
服务号